Endocrinology Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
Endocrinology Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Endocrinology Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Endocrinology Drugs 2013-2017, and development forecast 2018-2023
Main market players of Endocrinology Drugs in EMEA, with company and product introduction, position in the Endocrinology Drugs market
Market status and development trend of Endocrinology Drugs by types and applications
Cost and profit status of Endocrinology Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Endocrinology Drugs market as:
EMEA Endocrinology Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Endocrinology Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diabetes mellitus
Hyperthyroidism
Hypothyroidism
Pituitary acromegaly
Prolactinoma
Others
EMEA Endocrinology Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Thyroid hormone disorder drugs
Diabetes drugs
Human growth hormone
Testosterone replacement therapy
EMEA Endocrinology Drugs Market: Players Segment Analysis (Company and Product introduction, Endocrinology Drugs Sales Volume, Revenue, Price and Gross Margin):
Novo Nordisk
Sanofi
Merck
Eli Lily
AstraZeneca
AbbVie
Acerus Pharmaceuticals
Acrux DDS
Akros Pharma
Exsulin
Ferring Pharmaceuticals
Gan & Lee Pharmaceuticals
Genentech
Generex
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Endocrinology Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Endocrinology Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Endocrinology Drugs 2013-2017, and development forecast 2018-2023
Main market players of Endocrinology Drugs in EMEA, with company and product introduction, position in the Endocrinology Drugs market
Market status and development trend of Endocrinology Drugs by types and applications
Cost and profit status of Endocrinology Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Endocrinology Drugs market as:
EMEA Endocrinology Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Endocrinology Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Diabetes mellitus
Hyperthyroidism
Hypothyroidism
Pituitary acromegaly
Prolactinoma
Others
EMEA Endocrinology Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Thyroid hormone disorder drugs
Diabetes drugs
Human growth hormone
Testosterone replacement therapy
EMEA Endocrinology Drugs Market: Players Segment Analysis (Company and Product introduction, Endocrinology Drugs Sales Volume, Revenue, Price and Gross Margin):
Novo Nordisk
Sanofi
Merck
Eli Lily
AstraZeneca
AbbVie
Acerus Pharmaceuticals
Acrux DDS
Akros Pharma
Exsulin
Ferring Pharmaceuticals
Gan & Lee Pharmaceuticals
Genentech
Generex
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ENDOCRINOLOGY DRUGS
1.1 Definition of Endocrinology Drugs in This Report
1.2 Commercial Types of Endocrinology Drugs
1.2.1 Diabetes mellitus
1.2.2 Hyperthyroidism
1.2.3 Hypothyroidism
1.2.4 Pituitary acromegaly
1.2.5 Prolactinoma
1.2.6 Others
1.3 Downstream Application of Endocrinology Drugs
1.3.1 Thyroid hormone disorder drugs
1.3.2 Diabetes drugs
1.3.3 Human growth hormone
1.3.4 Testosterone replacement therapy
1.4 Development History of Endocrinology Drugs
1.5 Market Status and Trend of Endocrinology Drugs 2013-2023
1.5.1 EMEA Endocrinology Drugs Market Status and Trend 2013-2023
1.5.2 Regional Endocrinology Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Endocrinology Drugs in EMEA 2013-2017
2.2 Consumption Market of Endocrinology Drugs in EMEA by Regions
2.2.1 Consumption Volume of Endocrinology Drugs in EMEA by Regions
2.2.2 Revenue of Endocrinology Drugs in EMEA by Regions
2.3 Market Analysis of Endocrinology Drugs in EMEA by Regions
2.3.1 Market Analysis of Endocrinology Drugs in Europe 2013-2017
2.3.2 Market Analysis of Endocrinology Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Endocrinology Drugs in Africa 2013-2017
2.4 Market Development Forecast of Endocrinology Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Endocrinology Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Endocrinology Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Endocrinology Drugs in EMEA by Types
3.1.2 Revenue of Endocrinology Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Endocrinology Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Endocrinology Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Endocrinology Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Endocrinology Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Endocrinology Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Endocrinology Drugs by Downstream Industry in Africa
4.3 Market Forecast of Endocrinology Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ENDOCRINOLOGY DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Endocrinology Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ENDOCRINOLOGY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Endocrinology Drugs in EMEA by Major Players
6.2 Revenue of Endocrinology Drugs in EMEA by Major Players
6.3 Basic Information of Endocrinology Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Endocrinology Drugs Major Players
6.3.2 Employees and Revenue Level of Endocrinology Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ENDOCRINOLOGY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Novo Nordisk
7.1.1 Company profile
7.1.2 Representative Endocrinology Drugs Product
7.1.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.2 Sanofi
7.2.1 Company profile
7.2.2 Representative Endocrinology Drugs Product
7.2.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.3 Merck
7.3.1 Company profile
7.3.2 Representative Endocrinology Drugs Product
7.3.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Merck
7.4 Eli Lily
7.4.1 Company profile
7.4.2 Representative Endocrinology Drugs Product
7.4.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Eli Lily
7.5 AstraZeneca
7.5.1 Company profile
7.5.2 Representative Endocrinology Drugs Product
7.5.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.6 AbbVie
7.6.1 Company profile
7.6.2 Representative Endocrinology Drugs Product
7.6.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of AbbVie
7.7 Acerus Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Endocrinology Drugs Product
7.7.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Acerus Pharmaceuticals
7.8 Acrux DDS
7.8.1 Company profile
7.8.2 Representative Endocrinology Drugs Product
7.8.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Acrux DDS
7.9 Akros Pharma
7.9.1 Company profile
7.9.2 Representative Endocrinology Drugs Product
7.9.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Akros Pharma
7.10 Exsulin
7.10.1 Company profile
7.10.2 Representative Endocrinology Drugs Product
7.10.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Exsulin
7.11 Ferring Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Endocrinology Drugs Product
7.11.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
7.12 Gan & Lee Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative Endocrinology Drugs Product
7.12.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Gan & Lee Pharmaceuticals
7.13 Genentech
7.13.1 Company profile
7.13.2 Representative Endocrinology Drugs Product
7.13.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Genentech
7.14 Generex
7.14.1 Company profile
7.14.2 Representative Endocrinology Drugs Product
7.14.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Generex
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ENDOCRINOLOGY DRUGS
8.1 Industry Chain of Endocrinology Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ENDOCRINOLOGY DRUGS
9.1 Cost Structure Analysis of Endocrinology Drugs
9.2 Raw Materials Cost Analysis of Endocrinology Drugs
9.3 Labor Cost Analysis of Endocrinology Drugs
9.4 Manufacturing Expenses Analysis of Endocrinology Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ENDOCRINOLOGY DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Endocrinology Drugs in This Report
1.2 Commercial Types of Endocrinology Drugs
1.2.1 Diabetes mellitus
1.2.2 Hyperthyroidism
1.2.3 Hypothyroidism
1.2.4 Pituitary acromegaly
1.2.5 Prolactinoma
1.2.6 Others
1.3 Downstream Application of Endocrinology Drugs
1.3.1 Thyroid hormone disorder drugs
1.3.2 Diabetes drugs
1.3.3 Human growth hormone
1.3.4 Testosterone replacement therapy
1.4 Development History of Endocrinology Drugs
1.5 Market Status and Trend of Endocrinology Drugs 2013-2023
1.5.1 EMEA Endocrinology Drugs Market Status and Trend 2013-2023
1.5.2 Regional Endocrinology Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Endocrinology Drugs in EMEA 2013-2017
2.2 Consumption Market of Endocrinology Drugs in EMEA by Regions
2.2.1 Consumption Volume of Endocrinology Drugs in EMEA by Regions
2.2.2 Revenue of Endocrinology Drugs in EMEA by Regions
2.3 Market Analysis of Endocrinology Drugs in EMEA by Regions
2.3.1 Market Analysis of Endocrinology Drugs in Europe 2013-2017
2.3.2 Market Analysis of Endocrinology Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Endocrinology Drugs in Africa 2013-2017
2.4 Market Development Forecast of Endocrinology Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Endocrinology Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Endocrinology Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Endocrinology Drugs in EMEA by Types
3.1.2 Revenue of Endocrinology Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Endocrinology Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Endocrinology Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Endocrinology Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Endocrinology Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Endocrinology Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Endocrinology Drugs by Downstream Industry in Africa
4.3 Market Forecast of Endocrinology Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ENDOCRINOLOGY DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Endocrinology Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ENDOCRINOLOGY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Endocrinology Drugs in EMEA by Major Players
6.2 Revenue of Endocrinology Drugs in EMEA by Major Players
6.3 Basic Information of Endocrinology Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Endocrinology Drugs Major Players
6.3.2 Employees and Revenue Level of Endocrinology Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ENDOCRINOLOGY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Novo Nordisk
7.1.1 Company profile
7.1.2 Representative Endocrinology Drugs Product
7.1.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.2 Sanofi
7.2.1 Company profile
7.2.2 Representative Endocrinology Drugs Product
7.2.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.3 Merck
7.3.1 Company profile
7.3.2 Representative Endocrinology Drugs Product
7.3.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Merck
7.4 Eli Lily
7.4.1 Company profile
7.4.2 Representative Endocrinology Drugs Product
7.4.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Eli Lily
7.5 AstraZeneca
7.5.1 Company profile
7.5.2 Representative Endocrinology Drugs Product
7.5.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.6 AbbVie
7.6.1 Company profile
7.6.2 Representative Endocrinology Drugs Product
7.6.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of AbbVie
7.7 Acerus Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Endocrinology Drugs Product
7.7.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Acerus Pharmaceuticals
7.8 Acrux DDS
7.8.1 Company profile
7.8.2 Representative Endocrinology Drugs Product
7.8.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Acrux DDS
7.9 Akros Pharma
7.9.1 Company profile
7.9.2 Representative Endocrinology Drugs Product
7.9.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Akros Pharma
7.10 Exsulin
7.10.1 Company profile
7.10.2 Representative Endocrinology Drugs Product
7.10.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Exsulin
7.11 Ferring Pharmaceuticals
7.11.1 Company profile
7.11.2 Representative Endocrinology Drugs Product
7.11.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
7.12 Gan & Lee Pharmaceuticals
7.12.1 Company profile
7.12.2 Representative Endocrinology Drugs Product
7.12.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Gan & Lee Pharmaceuticals
7.13 Genentech
7.13.1 Company profile
7.13.2 Representative Endocrinology Drugs Product
7.13.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Genentech
7.14 Generex
7.14.1 Company profile
7.14.2 Representative Endocrinology Drugs Product
7.14.3 Endocrinology Drugs Sales, Revenue, Price and Gross Margin of Generex
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ENDOCRINOLOGY DRUGS
8.1 Industry Chain of Endocrinology Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ENDOCRINOLOGY DRUGS
9.1 Cost Structure Analysis of Endocrinology Drugs
9.2 Raw Materials Cost Analysis of Endocrinology Drugs
9.3 Labor Cost Analysis of Endocrinology Drugs
9.4 Manufacturing Expenses Analysis of Endocrinology Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ENDOCRINOLOGY DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
